Q-omics provides the consensus-scored MTND6P19 profile across patient tissues and cancer cell-line models. MTND6P19 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MTND6P19 is differentially expressed in 2, with the highest sampling consensus in READ. Additionally, MTND6P19 RNA expression shows 4,625 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight ACC, READ, and KIRC as cancer lineages where MTND6P19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTND6P19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTND6P19 survival associations across molecular data types. MTND6P19 RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTND6P19 RNA expression–survival associations across cancer types. High MTND6P19 expression shows unfavorable associations in ACC, DLBC, THYM and OV, but favorable associations in KICH and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MTND6P19 RNA expression.
This table summarizes MTND6P19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in READ for RNA.
This table ranks reproducible tumor–normal expression differences for MTND6P19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTND6P19 shows lower tumor expression in READ and KIRP. The READ box plot shows higher MTND6P19 RNA expression in normal versus tumor tissue (log2 FC = −0.160, t-test p = .033).
This table shows molecular features associated with MTND6P19 in patient tissues and cancer cell lines. In patient samples, MTND6P19 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
